Oncology Institute (TOI) director Kimberly Tzoumakas files initial Form 3

Rhea-AI Filing Summary

Oncology Institute, Inc. director Kimberly Jo Tzoumakas filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. This filing does not report any transactions or derivative positions and serves only to establish her reporting status with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/20/2026 - 04:34 PM Learn about SEC filing dates

FAQ

What does the TOI Form 3 filed by Kimberly Jo Tzoumakas show?

The Form 3 for Oncology Institute, Inc. (TOI) reports Kimberly Jo Tzoumakas’ initial status as a director. It is an opening ownership statement and, in this case, does not list any transactions or derivative securities positions.

Does the TOI Form 3 report any stock transactions by Kimberly Jo Tzoumakas?

No, this Form 3 does not report any buying or selling of TOI stock. The transactions section is empty, indicating there were no reportable trades or derivative exercises included in this initial ownership filing.

What role does Kimberly Jo Tzoumakas hold at Oncology Institute, Inc. (TOI)?

The filing identifies Kimberly Jo Tzoumakas as a director of Oncology Institute, Inc. Being a director makes her an insider under SEC rules, which triggers the requirement to file this Form 3 as an initial beneficial ownership statement.

Does this TOI Form 3 indicate any derivative securities for Kimberly Jo Tzoumakas?

No, the derivative securities section and related summary show no derivative positions. The derivativeTransactionCount and exerciseShares are zero, meaning no options, warrants, or similar instruments are reported in this initial filing.

What is the significance of a neutral netBuySellDirection in the TOI Form 3?

The neutral netBuySellDirection reflects that no purchases, sales, or other transactions were reported. For investors, this means the Form 3 is purely administrative, documenting insider status without signaling recent trading activity in TOI shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

TZOUMAKAS KIMBERLY JO

(Last) (First) (Middle)

18000 STUDEBAKER ROAD,

SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
02/23/2026

3. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 3, reporting an event occurring on February 23, 2026, is being filed late due to the reporting person's inability to obtain EDGAR access credentials prior to the applicable filing deadline, notwithstanding the initial submission of a completed Form ID application and related documents before such deadline. The reporting person is relying on the SEC Staff no-action position (Question 7, March 12, 2026), which provides relief for Section 16(a) filers who submitted a completed Form ID before a filing deadline falling between December 18, 2025 and March 18, 2026 but did not receive EDGAR access by the applicable filing deadline.

No securities are beneficially owned.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Kimberly J. Tzoumakas	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)